Phenomenex Expands Product Line with New Biozen dSEC-1 Size Exclusion Chromatography Column for Peptide Analysis

Next-Gen Midsize Biotherapeutic Characterization

September 25, 2025

TORRANCE, CA - Phenomenex Inc., a global leader in research, development and manufacturing of advanced technologies for the separation sciences, proudly announces the expansion of its Biozen product portfolio with Biozen dSEC-1 size exclusion chromatography (SEC) columns. As pivotal midsize biotherapeutics, such as peptides and oligonucleotides, continue to emerge, the demand for precise and efficient aggregate analysis increases to ensure purity of drugs. Commercially available columns present non-specific binding of analytes, resulting in unexpected chromatographic peaks that this innovative SEC column resolves by its intrinsic surface inertness.

"Current commercial SEC columns are not able to accommodate the small and highly hydrophilic nature of our nucleic acids," said Jongsu Yoo, Senior Scientist at OliX Pharmaceuticals. “With the dSEC-1 column, we were able to achieve resolution between duplex, sense, and, antisense strands of our target siRNA with minimal column interactions.”

The Biozen dSEC-1 SEC column delivers exceptional performance for researchers focused on midsize biotherapeutic characterization. Its inert silica-based matrix ensures minimal interaction with analytes, preserving conformations and enabling accurate profiling of low and high molecular weight species. The dSEC-1 column also provides robust, reproducible, and fast analysis under a variety of mobile phases without compromising column lifetime. The mechanical strength of the media allows using it under significantly higher back pressures when compared to commercially available SEC columns for these modalities.

This latest innovation from Phenomenex is part of our commitment to being a leader in chromatography solutions, empowering researchers and scientists with tools tailored to advance the frontiers of biotherapeutics. For more information about this product, please get in touch with our technical experts.

About Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in academic, pharmaceutical, biotech, environmental, clinical research, government, and industrial laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve human health and well-being. Phenomenex is an operating company within Danaher Corporation’s Life Sciences platform.

For more information, please visit www.phenomenex.com and follow the company's blog

Let’s connect: LinkedIn, Twitter, Facebook, Instagram and YouTube
Contact Information: Jannette Avila, Senior Manager, Brand and Public Relations jannettea@phenomenex.com | M: +1 (310) 212-0555